Section Arrow
GMAB.NASDAQ
- Genmab A/S ADS
Quotes are at least 15-min delayed:2024/10/31 19:50 EDT
Last
 22.33
-0.24 (-1.06%)
Day High 
22.4 
Prev. Close
22.57 
1-M High
24.31 
Volume 
964.93K 
Bid
22.2
Ask
23.12
Day Low
22.22 
Open
22.36 
1-M Low
22.39 
Market Cap 
14.33B 
Currency USD 
P/E 18.37 
%Yield -- 
10-SMA 22.9 
20-SMA 23.16 
50-SMA 25.06 
52-W High 32.89 
52-W Low 22.39 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
8.44/10.09
Enterprise Value
15.01B
Balance Sheet
Book Value Per Share
7.28
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
16.47B
Operating Revenue Per Share
3.80
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 19:50 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.